| 1 |
nonalcoholic fatty liver disease
(17373 times)
|
Gastroenterology
(4048 times)
|
NASH (3180 times)
HFD (1075 times)
BMI (957 times)
|
1998 Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.
|
| 2 |
nonalcoholic FLD
(7 times)
|
Gastroenterology
(4 times)
|
FLD (7 times)
AFLD (4 times)
ALD (1 time)
|
2006 Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
|
| 3 |
non-AFLD
(3 times)
|
Medical Informatics
(1 time)
|
AFLD (2 times)
AUC (1 time)
IMR-MS (1 time)
|
2009 A new ensemble-based algorithm for identifying breath gas marker candidates in liver disease using ion molecule reaction mass spectrometry.
|
| 4 |
NAFL disease
(2 times)
|
Gastroenterology
(1 time)
|
NAFL (2 times)
NASH (2 times)
HCF-1 (1 time)
|
2009 Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis.
|
| 5 |
NAFLD parents
(2 times)
|
Pediatrics
(2 times)
|
---
|
2014 Parental perceptions regarding lifestyle interventions for obese children and adolescents with nonalcoholic fatty liver disease.
|
| 6 |
nonalcoholic fatty LD
(2 times)
|
Pediatrics
(1 time)
|
LD (2 times)
LT (1 time)
MIS-C (1 time)
|
2012 Common Digestive and Liver Diseases among 5880 Patients Admitted to Shariati Hospital,Tehran,Iran during 2000-2009.
|
| 7 |
manifestation-nonalcoholic liver disease
(1 time)
|
Gastroenterology
(1 time)
|
---
|
2015 The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
|
| 8 |
NAFLD compared with controls
(1 time)
|
Inflammation
(1 time)
|
sCD14 (1 time)
sTNF-RII (1 time)
T2DM (1 time)
|
2010 Elevated endotoxin levels in non-alcoholic fatty liver disease.
|
| 9 |
NAFLD defined by ultrasound
(1 time)
|
Medicine
(1 time)
|
HP (1 time)
OR (1 time)
|
2022 Non-alcoholic fatty liver disease is not independently associated with Helicobacter pylori in a Central European screening cohort.
|
| 10 |
NAFLD fibrosis score, FibroMeter
(1 time)
|
Gastroenterology
(1 time)
|
APRI (1 time)
LSM (1 time)
|
2016 Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
|
| 11 |
NAFLD group
(1 time)
|
Pharmacology
(1 time)
|
BMI (1 time)
HbA1c (1 time)
HOMA (1 time)
|
2018 Analysis of the correlation between non-alcoholic fatty liver disease and bone metabolism indicators in healthy middle-aged men.
|
| 12 |
NAFLD mice treated with saline
(1 time)
|
Food
(1 time)
|
CON (1 time)
HFD (1 time)
PA (1 time)
|
2019 Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
|
| 13 |
NAFLD model among various liver diseases compare to control
(1 time)
|
Neoplasms
(1 time)
|
G-CSF (1 time)
|
2017 Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization.
|
| 14 |
NAFLD without HCC
(1 time)
|
Internal Medicine
(1 time)
|
BMI (1 time)
CRP (1 time)
HbA1c (1 time)
|
2017 The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
|
| 15 |
NAFLD-only
(1 time)
|
Gastroenterology
(1 time)
|
FLD (1 time)
MAFLD (1 time)
|
2021 Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
|
| 16 |
NFS.KEY MESSAGESNon-alcoholic fatty liver disease
(1 time)
|
Medicine
(1 time)
|
CI (1 time)
CP (1 time)
NFS (1 time)
|
2021 High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
|
| 17 |
Non alcoholic fatty liver disease and fibrosis
(1 time)
|
Medicine
(1 time)
|
APRI (1 time)
NFI (1 time)
|
2022 Comparison of Novel Fibrosis Index (NFI) with Aspartate aminotransferase to platelet ratio index (APRI) in Type II Diabetes mellitus patients with Non alcoholic fatty liver disease and fibrosis (NAFLD).
|
| 18 |
non-fatty liver disease
(1 time)
|
Chemistry
(1 time)
|
SPPARgammaM (1 time)
T2D (1 time)
|
2021 Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.
|
| 19 |
nonalcoholic fatty liver disease remains unknown
(1 time)
|
Complementary Therapies
(1 time)
|
MCD (1 time)
NASH (1 time)
|
2021 Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
|
| 20 |
number of HCCs developing on steatosis
(1 time)
|
Molecular Biology
(1 time)
|
HCC (1 time)
|
2017 Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
|
A Search Service for Abbreviation / Long Form